 |
|
Anti-psychotic drug use in the elderly increases despite drug safety warnings
August 26, 2008Three regulatory warnings of serious adverse events slowed the growth of use of atypical antipsychotic drugs among elderly patients with dementia, but they did not reduce the overall prescription rate of these drugs, found a research analysis of prescription drug claims data in Ontario http://www.cmaj.ca/press/pg438.pdf. The rate of use of these drugs actually increased 20% from the month prior to the first warning in September 2002 to the end of the study period in February 2007.
About 70% of people receiving antipsychotic drugs lived in nursing homes, and approximately 40% were aged 85 or older.
Three new atypical antipsychotic drugs approved for the treatment of schizophrenia and other related psychiatric conditions by Health Canada, however only one of them was approved for short term use to treat symptoms of aggression and psychosis in elderly patients with dementia. Between October 2002 and June 2005 Health Canada released three warning of increased risk of stroke or death in elderly patients with dementia taking these drugs.
Dr. Geoffrey Anderson and coauthors (Dr. Geoffrey Anderson, University of Toronto, 416-946-3770 or 416-480-6852) "found that the 3 warnings about serious adverse events associated with use of atypical antipsychotic agents in elderly people with dementia had a limited effect on the prescription rates of these agents. We also found that the overall rates of use of these drugs actually increased between the first warning in 2002 and the end of our follow-up in 2007."
"This finding highlights the limited impact of warnings and suggests that more effective approaches are needed to protect vulnerable populations from potentially hazardous medications," state the authors.
Some healthcare warnings fail to achieve the desired effect because the warnings have not provided physicians with information about the effectiveness and safety of alternative treatment options, writes Dr. Laurence Katz (Dr. Laurence Katz, University of Manitoba, 204-787-7564, LKatz@exchange.hsc.mb.ca) in a related commentary http://www.cmaj.ca/press/pg405.pdf. He states that health care warnings need to provide complete information about the risks and efficacy of the treatment and should identify alternative treatments.
Canadian Medical Association Journal
Dr. Geoffrey Anderson and coauthors (Dr. Geoffrey Anderson, University of Toronto, 416-946-3770 or 416-480-6852) "found that the 3 warnings about serious adverse events associated with use of atypical antipsychotic agents in elderly people with dementia had a limited effect on the prescription rates of these agents. We also found that the overall rates of use of these drugs actually increased between the first warning in 2002 and the end of our follow-up in 2007."
"This finding highlights the limited impact of warnings and suggests that more effective approaches are needed to protect vulnerable populations from potentially hazardous medications," state the authors.
Some healthcare warnings fail to achieve the desired effect because the warnings have not provided physicians with information about the effectiveness and safety of alternative treatment options, writes Dr. Laurence Katz (Dr. Laurence Katz, University of Manitoba, 204-787-7564, LKatz@exchange.hsc.mb.ca) in a related commentary http://www.cmaj.ca/press/pg405.pdf. He states that health care warnings need to provide complete information about the risks and efficacy of the treatment and should identify alternative treatments.
Canadian Medical Association Journal
Antipsychotic Current Events and Antipsychotic News RSSPitt research identifies new target in brain for treating schizophrenia
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug.
Glutamate: Too much of a good thing in schizophrenia?
Is schizophrenia a disorder of glutamate hyperactivity or hypoactivity? While the predominant hypothesis for many years was that schizophrenia was a glutamate deficit disorder, there is growing evidence of glutamate hyperactivity as well.
Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).
First generation antipsychotic drugs as effective as newer ones in some children
Nearly every child who receives an antipsychotic medicine is first prescribed one of the second-generation, or "atypical" drugs, such as olanzapine and risperidone. However, there has never been evidence that these drugs are more effective than the older, first-generation medications.
Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.
Looking beyond the drug receptor for clues to drug effectiveness
Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Estrogen relieves psychotic symptoms in women with schizophrenia
When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Violence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Hopkins researchers discover new link to schizophrenia
Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors.
More Antipsychotic Current Events and Antipsychotic News Articles
 | Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series) by Stephen M. Stahl Drawn from the best-selling second edition of Essential Psychopharmacology, Steve Stahl has revised and updated the chapters covering antipsychotics and mood stabilizers in this separate volume. This new book covers the many dimensions of psychosis, particularly as associated with schizophrenia, and examines the role of dopamine in psychosis along with the various theories about the causes,... |
 | Breakthroughs in Antipsychotic Medications: A Guide for Consumers, Families, and Clinicians. by Ronald J. Diamond, Patricia L. Scheifler, Ruth Ross, Ronald I. Diamond From the National Alliance for the Mentally Ill, this book gives consumers, their families, and clinicians information about antipsychotics that have recently become available. For people with schizophrenia and other psychotic disorders, antipsychotic medications are the key to recovery. Yet older medications have serious side effects and rarely affect symptoms like lethargy. New antipsychotics... |
 | Psychopharmacology of Antipsychotics by Stephen M. Stahl (Martin Dunitz) Univ. of California, San Diego. Pocket-sized text presents a series of visual lessons on the antipsychotic drugs. Figures and diagrams are based on the textbook Essential Psychopharmacology, c1996. Color illustrations. For clinicians and students. Trim size: 8.25 x 5.75 inches.... |
 | Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series) by Stephen M. Stahl Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr. Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this third edition of Antipsychotics and Mood Stabilizers. More than one-third longer than the previous edition, Antipsychotics and Mood Stabilizers is essential reading for professionals treating psychosis and students... |
 | America Fooled: The Truth About Antidepressants, Antipsychotics And How We've Been Deceived by Timothy Scott America Fooled is the non-sensational, fact-filled story of how Americans have come to believe that depression and other mental problems are caused by chemical imbalances which can be fixed with pills. It reveals how the drug studies used to achieve FDA approval are designed, paid for and written by the drug companies themselves and are purposely deceptive. Part 1 of America Fooled is focused on... |
| Antipsychotic Therapy in Children and Adolescents (Independent Study Offering) Audio cassette with... | |
| Antipsychotic Treatment Across the Continuum of Care : Independent Study Offering by Promedica Research | |
 | Metabolic Disturbances Associated with Antipsychotic Use (The Journal of Clinical Psychiatry Audiograph Series, Volume 4) by M.D. John W. Newcomer, M.D. David C. henderson, M.D. Harold E. Lebovitz, M.D. Herbert Y. Meltzer, M.D. Jonathan M. Meyer |
| Psychopharmacology of Atypical Antipsychotics Part 3 by Stephen Stahl | |
| Cardiac Complications of Antipsychotic Therapy: Independent Study Offering by Promedica Research |
| © 2008 BrightSurf.com |